Advertisement
Screener

Fortress Biotech, Inc. (FBIO) Noncash or Part Noncash Acquisition, Payables Assumed

2.1 / 5 stars · 40/95 Roast Me

Fortress Biotech, Inc. Noncash or Part Noncash Acquisition, Payables Assumed

Fortress Biotech, Inc. (FBIO) reported Noncash or Part Noncash Acquisition, Payables Assumed of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.

Discontinued › Cash Flow › Operating Activities

us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2018-03-16

  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2017-12-31 was $0.00.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2017-09-30 was -$192.00K, a 103.16% decline year-over-year.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2016-12-31 was $0.00.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for the quarter ending 2016-09-30 was $6.08M.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for fiscal 2016 was $6.08M.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for fiscal 2015 was $0.00.
  • Fortress Biotech, Inc. noncash or part noncash acquisition, payables assumed for fiscal 2014 was $0.00.
Period endNoncash or Part Noncash Acquisition, Payables Assumed 3 monthNoncash or Part Noncash Acquisition, Payables Assumed 6 monthNoncash or Part Noncash Acquisition, Payables Assumed 9 monthNoncash or Part Noncash Acquisition, Payables Assumed 9 month as first filedNoncash or Part Noncash Acquisition, Payables Assumed 12 monthNoncash or Part Noncash Acquisition, Payables Assumed 12 month as first filed
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
-$192.00K
derived: sum of 2 quarters · filed 2018-03-16
$0.00
10-K · filed 2018-03-16
2017-09-30-$192.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$0.00
10-Q · filed 2017-11-09
2017-06-30$192.00K
10-Q · filed 2017-08-09
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$6.08M
derived: sum of 2 quarters · filed 2018-03-16
$6.08M
10-K · filed 2018-03-16
-$6.08M
10-K · filed 2017-03-16
2016-09-30$6.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$6.08M
10-Q · filed 2017-11-09
-$6.08M
10-Q · filed 2016-11-09
2016-06-30$0.00
10-Q · filed 2017-08-09
2015-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
$0.00
10-K · filed 2018-03-16
2015-09-30$0.00
10-Q · filed 2016-11-09
2014-12-31$0.00
10-K · filed 2017-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Nkarta, Inc. (NKTX)United States$0.205B-1.73
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39